Overview
- The CNIO-led study published Monday, Sept. 28, 2026, shows that cancer cells arriving in the brain enter a temporary 'pausa proliferativa' in which the protein MXD4 suppresses the MYC growth program to survive.
- Preclinical tests in mice and experiments on human tumor samples found that the BCL-2 inhibitor venetoclax reduced micrometastases, with similar activity seen from ceralasertib, ATS-03 and obatoclax under the conditions studied.
- MXD4 does not act alone but blocks MYC-driven proliferation through downstream molecules, and blocking those cooperating pathways makes the dormant cells die rather than awaken and grow.
- There are no clinical trials yet because micrometastases cannot be detected with current diagnostics and validated biomarkers are lacking, so researchers propose initial prevention trials in patients after surgical removal of a brain metastasis.
- Next steps include finding biomarkers, choosing safe drug combinations and testing them in trial-ready settings using human tissue networks such as PEACE and RENACER, work that could cut the 30–50% one‑year recurrence risk after metastasis surgery.